Changing Patterns of Cancer Incidence in the Early- and Late-HAART Periods: the Swiss HIV Cohort Study

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Jul 1

PMID 20588274

Citations 126

Authors

S Franceschi

M Lise

G M Clifford

M Rickenbach

F Levi

M Maspoli

C Bouchardy

S Dehler

G Jundt

S Ess

A Bordoni

I Konzelmann

H Frick

L Dal Maso

L Elzi

H Furrer

A Calmy

M Cavassini

B Ledergerber

O Keiser

Affiliations

Soon will be listed here.

Abstract

Background: The advent of highly active antiretroviral therapy (HAART) in 1996 led to a decrease in the incidence of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), but not of other cancers, among people with HIV or AIDS (PWHA). It also led to marked increases in their life expectancy.

Methods: We conducted a record-linkage study between the Swiss HIV Cohort Study and nine Swiss cantonal cancer registries. In total, 9429 PWHA provided 20,615, 17,690, and 15,410 person-years in the pre-, early-, and late-HAART periods, respectively. Standardised incidence ratios in PWHA vs the general population, as well as age-standardised, and age-specific incidence rates were computed for different periods.

Results: Incidence of KS and NHL decreased by several fold between the pre- and early-HAART periods, and additionally declined from the early- to the late-HAART period. Incidence of cancers of the anus, liver, non-melanomatous skin, and Hodgkin's lymphoma increased in the early- compared with the pre-HAART period, but not during the late-HAART period. The incidence of all non-AIDS-defining cancers (NADCs) combined was similar in all periods, and approximately double that in the general population.

Conclusions: Increases in the incidence of selected NADCs after the introduction of HAART were largely accounted for by the ageing of PWHA.

Citing Articles

The Management of Hematopoietic Stem Cell Transplant in People with HIV.

Dickter J, Moc Willeford C Viruses. 2024; 16(10).

PMID: 39459894 PMC: 11512245. DOI: 10.3390/v16101560.

Safety and Immunogenicity of the Nonavalent Human Papillomavirus Vaccine in Women Living with HIV.

Hidalgo-Tenorio C, Moya R, Omar M, Munoz L, Sampedro A, Lopez-Hidalgo J Vaccines (Basel). 2024; 12(8).

PMID: 39203964 PMC: 11359547. DOI: 10.3390/vaccines12080838.

Navigating the Nexus: HIV and Breast Cancer-A Critical Review.

Marino A, Pavone G, Martorana F, Fisicaro V, Motta L, Spampinato S Int J Mol Sci. 2024; 25(6).

PMID: 38542195 PMC: 10970700. DOI: 10.3390/ijms25063222.

Cancer and HIV: The Molecular Mechanisms of the Deadly Duo.

Omar A, Marques N, Crawford N Cancers (Basel). 2024; 16(3).

PMID: 38339297 PMC: 10854577. DOI: 10.3390/cancers16030546.

A clinical overview of people living with HIV and genitourinary cancer care.

Suk-Ouichai C, Coghill A, Schabath M, Sanchez J, Chahoud J, Necchi A Nat Rev Urol. 2024; 21(6):373-383.

PMID: 38238527 DOI: 10.1038/s41585-023-00846-8.

References

Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro-Murillo A . Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009; 14(8):1065-74. PMC: 2821596. DOI: 10.3851/IMP1462. View

Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M . Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat. 2007; 14(3):183-8. DOI: 10.1111/j.1365-2893.2006.00791.x. View

Polesel J, Clifford G, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C . Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2007; 22(2):301-6. DOI: 10.1097/QAD.0b013e3282f2705d. View

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F . A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009; 10(4):321-2. DOI: 10.1016/s1470-2045(09)70096-8. View

Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L . Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008; 22(10):1203-11. DOI: 10.1097/QAD.0b013e3283023f78. View

Clifford G, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A . Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005; 97(6):425-32. DOI: 10.1093/jnci/dji072. View

Dal Maso L, Braga C, Franceschi S . Methodology used for "software for automated linkage in Italy" (SALI). J Biomed Inform. 2002; 34(6):387-95. DOI: 10.1006/jbin.2002.1036. View

Hammer S, Eron Jr J, Reiss P, Schooley R, Thompson M, Walmsley S . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-70. DOI: 10.1001/jama.300.5.555. View

Kirk G, Merlo C, O Driscoll P, Mehta S, Galai N, Vlahov D . HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45(1):103-10. PMC: 4078722. DOI: 10.1086/518606. View

10.

Clifford G, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B . Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008; 22(16):2135-41. DOI: 10.1097/QAD.0b013e32831103ad. View

11.

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B . Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2008; 27(6):884-90. DOI: 10.1200/JCO.2008.19.6626. View

12.

Ancelle-Park R . Expanded European AIDS case definition. Lancet. 1993; 341(8842):441. DOI: 10.1016/0140-6736(93)93040-8. View

13.

Breslow N, Day N . Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987; (82):1-406. View

14.

Chaturvedi A, Madeleine M, Biggar R, Engels E . Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. 2009; 101(16):1120-30. PMC: 2728745. DOI: 10.1093/jnci/djp205. View

15.

Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R . All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS. 2004; 18(13):1835-43. DOI: 10.1097/00002030-200409030-00013. View

16.

Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F . Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer. 2009; 100(5):840-7. PMC: 2653754. DOI: 10.1038/sj.bjc.6604923. View

17.

Weber R, Sabin C, Friis-Moller N, Reiss P, El-Sadr W, Kirk O . Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006; 166(15):1632-41. DOI: 10.1001/archinte.166.15.1632. View

18.

Guiguet M, Boue F, Cadranel J, Lang J, Rosenthal E, Costagliola D . Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009; 10(12):1152-9. DOI: 10.1016/S1470-2045(09)70282-7. View

19.

. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. IARC Monogr Eval Carcinog Risks Hum. 1997; 70:1-492. PMC: 5046075. View

20.

Puoti M, Bruno R, Soriano V, Donato F, Gaeta G, Quinzan G . Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004; 18(17):2285-93. DOI: 10.1097/00002030-200411190-00009. View